Moxifloxacin-
1 Inquiries
151096-09-2
Pharmaceutical Grade
98%
shanghai
1kg
2026-07-25
amino acid derivatives,pharmaceutical intermediates,oligonucleotide reagent
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceMoxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039), used to treat a number of infections, including: respiratory tract infections, cellulitis, anthrax, intraabdominal infections, endocarditis, meningitis, and tuberculosis. It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intrav
Solid
Moxifloxacin is a quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents. It has a role as an antibacterial drug. It is a quinolinemonocarboxylic acid, a quinolone, a member of cyclopropanes, a pyrrolidinopiperidine, an aromatic ether, a quinolone antibiotic and a fluoroquinolone antibiotic. It is a conjugate base of a moxifloxacinium(1+).|Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.|Moxifloxacin is a Quinolone Antimicrobial.|Moxifloxacin is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.|Moxifloxacin is a fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.|A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.Basic Info-
Product Name:
Moxifloxacin
Other Name:3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-;3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-,(4aS-cis)-;6H-Pyrrolo[3,4-b]pyridine,3-quinolinecarboxylic acid deriv.;1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid;Moxifloxacin;Vigamox;Izilox;Moxifloxacine;Avolex;Moxeza;Rapiflox;Moxicip;195154-07-5
CAS No.:151096-09-2
Molecular Formula:C21H24FN3O4
InChIKeys:InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N
Molecular Weight:401.43
Exact Mass:401.43
EC Number:1806241-263-5
UNII:U188XYD42P
DSSTox ID:DTXSID3048491
NCI Thesaurus Code:C62052
ATC Code:J01MA14|J - Antiinfectives for systemic use|S - Sensory organs
Categories:
Characteristics-
PSA:
82.1
XLogP3:2.9
Appearance:Solid
Density:1.408±0.06 g/cm3(Predicted)
Melting Point:240 °C
Boiling Point:636.4°C at 760 mmHg
Flash Point:338.7ºC
Refractive Index:1.633
Water Solubility:1.68e-01 g/L
Storage Conditions:Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity. /Moxifloxacin hydrochloride/
Vapor Pressure:7.26X10-15 mm Hg at 25 deg C (est)
Specific rotation:23D -193°
Henrys Law Constant:Henry's Law constant = 3.11X10-20 atm-cu m/mol at 25 °C (est)
Collision Cross Section:198.5 Ų [M+H]+ [CCS Type: TW, Method: calibrated with Waters Major Mix]|210.7 Ų [M+Na]+ [CCS Type: TW, Method: calibrated with Waters Major Mix]|202.63 Ų [M-H]-
Experimental Properties:Slightly yellow to yellow crystalline powder, mp 324-325 °C (decomposes), specific optical rotation: -256 °C at 25 °C/D (c = 0.5 in water) /Moxifloxacin hydrochloride/|Hydroxyl radical reaction rate constant = 1.28X10-10 cu cm/molec-sec at 25 °C (est)|Ozone radical reaction rate constant = 1.75X10-18 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Eye irritation, Category 2
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 3
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
H319 Causes serious eye irritation
H412 Harmful to aquatic life with long lasting effects
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P273 Avoid release to the environment.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
amino acid derivatives,pharmaceutical intermediates,oligonucleotide reagent
-
Location:
41-1402, CECEP, No.18 Dongchang Road, Suzhou Industrial Park, Jiangsu Province, 215126 China
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
10
-
Total Annual Revenue:
$10 million-$25 million
-
Year of Establishment:
2014
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
South Korea
Moxifloxacin
1 KG Jun 25, 2026 Post an enquiry for this product
